^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Esophageal Cancer

Related cancers:
15h
New P2 trial
|
CD163 (CD163 Molecule)
|
carboplatin • metformin
15h
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma (clinicaltrials.gov)
P=N/A, N=28, Completed, NovoCure Ltd. | Unknown status --> Completed | Trial completion date: Sep 2021 --> Jun 2024 | Trial primary completion date: Sep 2021 --> Jun 2024
Trial completion • Trial completion date • Trial primary completion date
|
Herceptin (trastuzumab) • capecitabine • oxaliplatin
16h
Serplulimab Combined with Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Active, not recruiting
Enrollment closed
|
carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
19h
A Prospective Study Frailty for Esophagectomy and Lung Resection in Thoracic Surgery (clinicaltrials.gov)
P=N/A, N=360, Completed, The Cleveland Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Nov 2024
Trial completion • Trial completion date
1d
New trial
|
VIM (Vimentin) • CCNA1 (Cyclin A1)
2d
New trial
2d
IDeate-Pantumor 01: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov)
P1/2, N=250, Recruiting, Daiichi Sankyo | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date
|
ifinatamab deruxtecan (DS-7300)
3d
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=40, Recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
3d
New P2 trial
|
Irene (pyrotinib) • AiRuiKang (dalpiciclib)
3d
New P2 trial
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
|
SMARCA4 mutation • SMARCA4 deletion
|
Keytruda (pembrolizumab) • PRT3789
3d
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov)
P1/2, N=56, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Trodelvy (sacituzumab govitecan-hziy)
4d
Application of preoperative thoracoscopic-guided paravertebral block in the perioperative period of thoracoscopic-laparscopic esophagectomy (ChiCTR2400091153)
P=N/A, N=120, Recruiting, Ningbo Medical Center Lihuili Hospital; Ningbo Medical Center Lihuili Hospital
New trial
4d
Correlation between perioperative fluid therapy and surgical prognosis of gastrointestinal malignancies (ChiCTR2400090619)
P=N/A, N=10000, Not yet recruiting, The First Affiliated Hospital of Air Force Military Medical University; The First Affiliated Hospital of the Air Force Military Medical University
New trial
4d
The Construction and Preliminary Application of Thirst Management Scheme for Esophageal Cancer Patients during Perioperative Period (ChiCTR2400090691)
P=N/A, N=173, Recruiting, The Second Affiliated Hospital of Soochow University; The Second Affiliated Hospital of Soochow University
New trial
4d
New trial • Surgery
4d
Clinical efficacy of robot-assisted combined thoraco-abdominal surgery for gastroesophageal junction tumor (ChiCTR2400090427)
P=N/A, N=50, Not yet recruiting, Second Hospital of Lanzhou University; Second Hospital of Lanzhou University
New trial • Surgery
4d
New trial • HEOR
4d
A novel submucosa steroid injection strategy to prevent esophageal stricture following circumferential endoscopic submucosal dissection of esophagus superficial cancer (ChiCTR2400090469)
P=N/A, N=106, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
New trial
4d
Effects of a perioperative rehabilitation program on postoperative complications and quality of life in patients with esophageal cancer (ChiCTR2400090172)
P=N/A, N=60, Recruiting, The Sixth Affiliated Hospital, Sun Yat-sen University; The Sixth Affiliated Hospital, Sun Yat-sen University
New trial • HEOR
4d
PET/CT imaging of Gallium-68 labeled FAP probes in patients with solid tumors (ChiCTR2400089998)
P=N/A, N=0, Recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
New trial
4d
New trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
4d
Low-dose re-irradiation combined with chemotherapy and PD-1 for local primary-recurrence esophageal cancer: A prospective, single-arm clinical study (ChiCTR2400089694)
P=N/A, N=32, Not yet recruiting, Jiangsu Province Hospital, the first affiliated hospital of Nanjing Medical University; Jiangsu Province Hospital, the first affiliated hospital of Na
New trial
4d
Effect of different neoadjuvant treatment regimens on intraoperative hypotension and postoperative related complications in patients with esophageal cancer: a real-world study (ChiCTR2400089724)
P=N/A, N=1500, Recruiting, Jiangsu Cancer Hospital(The affliated Cancer Hospital of Nanjing Medical University); Jiangsu Cancer Hospital
New trial • Real-world evidence • Real-world
|
CRP (C-reactive protein)
4d
New trial
|
ICAM1 (Intercellular adhesion molecule 1)
4d
Compared with 3D and 2D cavity mirror cavity mirror minimally invasive surgical treatment of esophageal prospective, randomized, controlled multicenter study (ChiCTR2400089561)
P=N/A, N=106, Not yet recruiting, Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
New trial
4d
New trial • Surgery
4d
An innovative cohort of gastric cancer patients in China was established based on the tumor information database of the National Cancer Center to carry out continuous retrospective study (ChiCTR2400089294)
P=N/A, N=100000, Recruiting, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll
New trial
4d
A single-arm exploratory clinical study of penpulimab combined with anlotinib in the first-line treatment of advanced esophageal squamous cell carcinoma (ChiCTR2400089133)
P=N/A, N=30, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
New trial • Metastases
|
Focus V (anlotinib) • albumin-bound paclitaxel • Anniko (penpulimab)
4d
The effect of esketamine on early postoperative recovery quality in patients undergoing minimally invasive esophagectomy: a randomized controlled study (ChiCTR2400088916)
P=N/A, N=210, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New trial
4d
New P4 trial
|
oxaliplatin • Lonsurf (trifluridine/tipiracil)
4d
New P4 trial • Metastases
|
cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr)
4d
New P4 trial • Real-world evidence • Real-world • Metastases
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
4d
New P2 trial • Metastases
|
Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
4d
A Prospective, Multicenter Clinical Study of the Efficacy and Safety of First-Line Treatment with Ivonescimab in Combination with XELOX for Unresectable Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (ChiCTR2400089954)
P2, N=30, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
New P2 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
capecitabine • oxaliplatin • Yidafan (ivonescimab)
4d
New P2 trial • Combination therapy
|
Keytruda (pembrolizumab)
4d
New P2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
4d
An open-label and multicenter Phase Ⅰ Clinical Study to Evaluate the Safety and Efficacy of SYS6010 in combination with Enlonstobart and Simmitinib in patients with advanced esophageal cancer (ChiCTR2400089300)
P1, N=60, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology; The First Affiliated Hospital of Henan University of Science and Technolo
New P1 trial • Combination therapy • Metastases
|
Enshuxing (enlonstobart) • simmitinib (SYHA1817)
4d
PET imaging of [18F]AlF-ETN for assessment of EphA2 Presence in Solid Tumors (ChiCTR2400090839)
P1, N=25, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences Union Medical College; Cancer Hospital Chinese Academy of Medical Sciences
New P1 trial
4d
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • HER-2 negative